Recombinant multi-species Semenogelin-1/SEMG1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine Semenogelin-1/SEMG1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene is the predominant protein in semen. The encoded secreted protein is involved in the formation of a gel matrix that encases ejaculated spermatozoa. This preproprotein is proteolytically processed by the prostate-specific antigen (PSA) protease to generate multiple peptide products that exhibit distinct functions. One of these peptides, SgI-29, is an antimicrobial peptide with antibacterial activity. This proteolysis process also breaks down the gel matrix and allows the spermatozoa to move more freely. This gene and another similar semenogelin gene are present in a gene cluster on chromosome 20. [provided by RefSeq, Feb 2016]
The Alternative Names of target: CT103,Cancer/testis antigen 103,SEMG,SEMG1,SGI,Semenogelin I (SGI),Semenogelin-1,dJ172H20.2

Target products collectionGo to Semenogelin-1/SEMG1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-SE1275-Ag-1/ GM-Tg-hg-SE1275-Ag-2 Human Semenogelin-1/SEMG1 protein Human
GM-Tg-rg-SE1275-Ag-1/ GM-Tg-rg-SE1275-Ag-2 Rat Semenogelin-1/SEMG1 protein Rat
GM-Tg-mg-SE1275-Ag-1/ GM-Tg-mg-SE1275-Ag-2 Mouse Semenogelin-1/SEMG1 protein Mouse
GM-Tg-cynog-SE1275-Ag-1/ GM-Tg-cynog-SE1275-Ag-2 Cynomolgus/Rhesus macaque Semenogelin-1/SEMG1 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-SE1275-Ag-1/ GM-Tg-felg-SE1275-Ag-2 Feline Semenogelin-1/SEMG1 protein Feline
GM-Tg-cang-SE1275-Ag-1/ GM-Tg-cang-SE1275-Ag-2 Canine Semenogelin-1/SEMG1 protein Canine
GM-Tg-bovg-SE1275-Ag-1/ GM-Tg-bovg-SE1275-Ag-2 Bovine Semenogelin-1/SEMG1 protein Bovine
GM-Tg-equg-SE1275-Ag-1/ GM-Tg-equg-SE1275-Ag-2 Equine Semenogelin-1/SEMG1 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-SE1275-Ag-1/ GM-Tg-hg-SE1275-Ag-2; GM-Tg-rg-SE1275-Ag-1/ GM-Tg-rg-SE1275-Ag-2;
GM-Tg-mg-SE1275-Ag-1/ GM-Tg-mg-SE1275-Ag-2; GM-Tg-cynog-SE1275-Ag-1/ GM-Tg-cynog-SE1275-Ag-2;
GM-Tg-felg-SE1275-Ag-1/ GM-Tg-felg-SE1275-Ag-2; GM-Tg-cang-SE1275-Ag-1/ GM-Tg-cang-SE1275-Ag-2;
GM-Tg-bovg-SE1275-Ag-1/ GM-Tg-bovg-SE1275-Ag-2; GM-Tg-equg-SE1275-Ag-1/ GM-Tg-equg-SE1275-Ag-2
Products Name Semenogelin-1/SEMG1 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name Semenogelin-1/SEMG1
Protein Sub-location Secreted Protein/Potential Cytokines
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine Semenogelin-1/SEMG1 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.